LOTEPREDNOL ETABONATE - Generic Drug Details

What are the generic drug sources for loteprednol etabonate and what is the scope of freedom to operate?

Loteprednol etabonate is the generic ingredient in eight branded drugs marketed by Bausch And Lomb Inc, Hikma, Lupin Ltd, Sentiss, Sun Pharm, Bausch And Lomb, Alcon Labs Inc, Pharmos, Amneal, Padagis Us, and Alembic, and is included in twenty-three NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Loteprednol etabonate has one hundred and twenty-four patent family members in seventeen countries.

There are ten drug master file entries for loteprednol etabonate. Twelve suppliers are listed for this compound.

Summary for LOTEPREDNOL ETABONATE

International Patents:	124
US Patents:	22
Tradenames:	8
Applicants:	11
NDAs:	23
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	48
Patent Applications:	7,254
Drug Prices:	Drug price trends for LOTEPREDNOL ETABONATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LOTEPREDNOL ETABONATE
What excipients (inactive ingredients) are in LOTEPREDNOL ETABONATE?	LOTEPREDNOL ETABONATE excipients list
DailyMed Link:	LOTEPREDNOL ETABONATE at DailyMed

See drug prices for LOTEPREDNOL ETABONATE

Recent Clinical Trials for LOTEPREDNOL ETABONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Price Vision Group	Phase 4
Kala Pharmaceuticals, Inc.	Phase 4
Retina Research Institute, LLC	PHASE4

See all LOTEPREDNOL ETABONATE clinical trials

Pharmacology for LOTEPREDNOL ETABONATE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for LOTEPREDNOL ETABONATE

Anti-Allergic Agents

Anatomical Therapeutic Chemical (ATC) Classes for LOTEPREDNOL ETABONATE

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LOTEPREDNOL ETABONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOTEMAX SM	Ophthalmic Gel	loteprednol etabonate	0.38%	208219	1	2022-11-14

US Patents and Regulatory Information for LOTEPREDNOL ETABONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	LOTEPREDNOL ETABONATE	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	217484-001	May 20, 2025	AB	RX	No	No
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes			Y

Expired US Patents for LOTEPREDNOL ETABONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmos	LOTEMAX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020841-001	Mar 9, 1998
Bausch And Lomb Inc	LOTEMAX	loteprednol etabonate	GEL;OPHTHALMIC	202872-001	Sep 28, 2012
Pharmos	LOTEMAX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020841-001	Mar 9, 1998

International Patents for LOTEPREDNOL ETABONATE

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3062796	COMPOSITIONS ET PROCÉDÉS POUR APPLICATIONS OPHTALMIQUES ET/OU AUTRES APPLICATIONS (COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS)
New Zealand	733080	Pharmaceutical nanoparticles showing improved mucosal transport
Poland	3721868

LOTEPREDNOL ETABONATE: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the current market footprint for loteprednol etabonate?

Loteprednol etabonate is a corticosteroid marketed for ophthalmic inflammation and related conditions. The commercial market is dominated by prescription-and-generic supply chains, with product form factors (suspension and gel/ointment) and dosing convenience shaping share more than pipeline innovation.

Market structure (how the category typically monetizes)

• Therapeutic class: Ophthalmic corticosteroids.
• Primary demand drivers: Post-operative inflammation and chronic inflammatory eye conditions treated in ophthalmology settings.
• Customer and channel: Retail pharmacies, mail-order, and clinic/ASC formularies via ophthalmology and surgical demand cycles.
• Competition profile: Multi-brand and generic ophthalmic steroids; price competition rises after entry of authorized generics and non-authorized generics (label-to-label substitutions depend on formulation and dosing match).

Commercial implication for loteprednol etabonate

Loteprednol etabonate’s revenue is structurally tied to:

• Product lifecycle and generic availability in specific dosage forms.
• Switchability versus other ophthalmic steroid options based on dosing frequency and formulation.
• Seasonality and procedure volume through ophthalmic surgery scheduling (cataract and related procedures drive a large share of steroid demand).

How have pricing and competition evolved across the lifecycle?

The ophthalmic steroid market generally shifts through three phases:

1. Brand penetration: Higher price tolerance when prescribers trust a specific formulation for onset and tolerability.
2. Generic encroachment: Lower net prices driven by generic competition and payer preferences.
3. Constrained differentiation: Margin pressure persists; differentiation depends on dosing convenience, formulation attributes, and clinical comfort.

For loteprednol etabonate specifically, the financial trajectory is expected to reflect that pathway: incremental share gains are harder to sustain once multiple generics exist in the same labeled indication space, while brand pricing power weakens.

What does the financial trajectory typically look like (revenue, margin, and cash-flow)?

Revenue trajectory (directionally)

• Initial and mid lifecycle: Steady revenue growth when branded product and formulations capture surgeon and ophthalmologist prescribing.
• Late lifecycle: Revenue flattens and then declines as generic penetration expands and payers push cost-effective alternatives.
• Stabilization band: Some erosion slows after patent-expiry-driven generic “first wave,” but net price pressure continues.

Margin and cash-flow dynamics

• Gross margin compression: As generics increase, the branded net realized price falls.
• COGS and supply chain: Manufacturing costs do not fall as fast as net pricing, pressuring contribution margin.
• Working capital: Demand variability tied to procedure scheduling can affect inventory cycles.
• Marketing spend: Brand marketing typically shifts from growth to retention, with spend increasingly scrutinized by payers.

What market events matter most for financial performance?

Even when clinical updates do not change guidelines materially, the financial trajectory often hinges on:

• Patent and exclusivity milestones (filings, approvals, and launch dates).
• Generic entry timing by dosage form and strength.
• Formulary and payer coverage changes in ophthalmology benefit design.
• Label expansions or narrowing that shift the addressable patient pool.
• Supply disruptions (if they occur) that temporarily lift pricing but usually do not reverse long-term erosion.

For investor-grade analysis, the key is that ophthalmic steroid revenue is sensitive to regulatory exclusivity windows and generic entry schedules more than to incremental competitive messaging.

Which product forms most influence commercial outcomes?

Market behavior in ophthalmic steroids depends heavily on:

• Dosing frequency (fewer daily doses can improve persistence and payer acceptance).
• Formulation type (suspension versus gel/ointment often changes patient adherence and prescriber preference).
• Titration and discontinuation patterns after surgery.
• Perceived tolerability (burning/stinging complaints can shift prescribing away from certain options).

Loteprednol etabonate’s commercial trajectory therefore tracks the performance of its specific dosage forms within each labeled context, not the molecule in the abstract.

How does payer behavior change net prices for loteprednol etabonate?

Payer behavior tends to evolve as:

• Early on, payers cover branded products with prior authorization or limited step edits.
• After generic entry, payers reduce coverage breadth for higher-priced options and impose step therapy or narrow formularies.

The result is typically:

• Lower net revenue for branded products.
• Higher volumes but reduced economics for distributors and manufacturers once generic share dominates.

What is the competitive benchmark inside ophthalmic corticosteroids?

The relevant benchmark is not one drug but the set of ophthalmic steroid options available under similar clinical pathways. Loteprednol etabonate competes against:

• Other marketed ophthalmic steroids with overlapping indications.
• Generic equivalents when available for the same formulation and strength.
• Alternative steroid-like agents in specific subpopulations if payers prefer a cost-effective tier.

Competitive intensity is high because ophthalmic steroids are generally considered substitutable in practice when label overlap exists, and because generic penetration is common.

What are the expected financial implications of generic entry?

Generic entry usually causes:

• Abrupt net price drops in the first quarters post-launch.
• Volume share reshuffling as pharmacies and prescribers switch to lower cost alternatives.
• Reduced long-term brand share unless a manufacturer sustains differentiation through formulation, adherence benefit, or patient-specific use.

For loteprednol etabonate, the financial trajectory after generic encroachment is dominated by net price erosion and channel-driven switching rather than by incremental clinical uptake.

What does this mean for market outlook by 1 to 5 years?

Near term:

• Revenue stays sensitive to generic mix and payer formulary management.
• Product-level performance depends on whether branded versions retain a niche in dosing convenience or prescriber preference.

Medium term:

• Continued competitive pressure from generics keeps margin structure tight.
• Growth depends on procedure volume and any formulation or label changes that expand addressable utilization.

Long term:

• Without a material exclusivity extension or meaningful differentiation, the economics of the category trend toward low-margin commoditization.

What should decision-makers monitor to track financial trajectory?

A rigorous monitoring list for loteprednol etabonate economics:

• Quarterly net sales by dosage form and territory.
• Generic launch cadence and utilization share by NDC.
• Formulary tier moves (commercial, Medicare, Medicaid) affecting ophthalmic steroid coverage.
• Prescription counts versus net price (distinguish volume growth from price decline).
• Channel inventory signals (sell-through versus stocking changes).

Key Takeaways

• Loteprednol etabonate’s market economics follow the typical ophthalmic steroid lifecycle: brand-led uptake then sustained net price erosion once generics dominate.
• Financial performance is driven more by exclusivity timelines, generic entry scheduling, and payer formulary behavior than by incremental clinical repositioning.
• Future revenue and margin stability depend on product form factor differentiation (dosing and formulation) and procedure-driven demand volumes, not on broad pipeline dynamics.

FAQs

1. Is loteprednol etabonate primarily a surgery-driven market?
   Prescription volume correlates strongly with ophthalmic procedure volume, since postoperative inflammation treatment consumes a large share of ophthalmic steroid demand.

2. Do payer formularies materially affect net realized price for ophthalmic steroids?
   Yes. After generic entry, payers commonly tighten preferred coverage and use step therapy or tiering, which compresses net pricing for branded products.

3. What determines whether patients switch away from a branded ophthalmic steroid?
   The main drivers are cost differences, dosing frequency, formulation substitution match, and prescriber comfort with alternatives.

4. How should companies track loteprednol etabonate financial health post-launch of generics?
   Monitor both net sales and prescription volume by NDC, and cross-check against formulary tier changes and generic share shifts.

5. What is the highest-leverage lever for protecting revenue in this category?
   Maintaining coverage and differentiation at the product-form level (dosing convenience, formulation usability) while managing competitive pricing pressure after exclusivity erosion.

---

References

[1] Bloomberg Government (drug and exclusivity analytics).
[2] FDA Orange Book (patent and exclusivity status for drug products containing loteprednol etabonate).
[3] IQVIA Institute / IQVIA forecasting and market insights (ophthalmology category dynamics).
[4] CMS Part D/Medicare formulary utilization reporting (payer coverage trends relevant to ophthalmic therapeutics).